This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

N-acetylcysteine in Bulimia Nervosa

This study has been terminated.
Information provided by (Responsible Party):
Lindner Center of HOPE Identifier:
First received: May 24, 2010
Last updated: May 8, 2013
Last verified: May 2013
This study tests NAC in the treatment of Bulimia Nervosa.

Condition Intervention Phase
NAC Drug: N-acetylcysteine NAC Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Lindner Center of HOPE:

Primary Outcome Measures:
  • Binge-purge episodes [ Time Frame: per week ]
    The primary outcome measure will be the weekly frequency of binge-purge episodes. A binge-purge eating episode will be defined using DSM-IV-TR criteria, and accessed via clinical interview and review of subject take-home diaries at each study visit.

Enrollment: 11
Study Start Date: February 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
open label treatment. Each subject receives N-acetylcysteine.
Drug: N-acetylcysteine NAC
N-acetylcysteine in the treatment of Bulimia Nervosa


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Bulimia Nervosa
  • 18-65 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01131572

United States, Ohio
Lindner Center of HOPE
Mason, Ohio, United States, 45040
Sponsors and Collaborators
Lindner Center of HOPE
  More Information

Additional Information:
Responsible Party: Lindner Center of HOPE Identifier: NCT01131572     History of Changes
Other Study ID Numbers: IRB19223, 09-09-18-01
Study First Received: May 24, 2010
Last Updated: May 8, 2013

Additional relevant MeSH terms:
Antiviral Agents
Anti-Infective Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes processed this record on September 21, 2017